

DEPARTMENT OF

HEALTH AND HUMAN SERVICES

DIVISION OF HEALTH CARE FINANCING AND POLICY Helping people. It's who we are and what we do.



Stacie Weeks, JD MPH Administrator

Drug Utilization Review

Board Meeting Minutes

Date of Meeting: Thursday, April 20, 2023

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Drug Use Review Board

Agenda Item	Record			Notes
1. Call to Order and Roll Call	It was announced the meeting is being record	DHCFP Staff Present were as follows:		
	Chairperson Wheeler called the meeting to order at 1:05 p.m. on April 20, 2023.			 Griffin, Karen, Senior Deputy Attorney General (SDAG) Olsen, David, Chief of Pharmacy Services
	Chairperson Wheeler took the roll.			Gudino, Antonio, Manager of
		Dracant	Abcont	Pharmacy Services
		Present	Absent	Clemons, Roshanda, Medical Director
	• Jennifer Wheeler, Pharm.D., Chair	\boxtimes		 Berntson, Kindra, Social Services Program Specialist II (SSPS II),
	• Netochi Adeolokun, Pharm.D., Vice Chair	\boxtimes		Pharmacy Unit
	Mark Canty, MD	\boxtimes		 Flowers, Ellen, Program Officer I,
	Crystal Castaneda, MD	\boxtimes		Pharmacy Unit
	Jessica Cate, Pharm.D.		\boxtimes	
	Dave England, Pharm.D.	\boxtimes		Magellan Rx Staff Present were as
	Brain Le, DO		\boxtimes	follows:
	Rebecca Sparks, PA-C	\boxtimes		Mishra, Raj, Pharm.D., Clinical Account
	• Jim Tran, Pharm.D.	\boxtimes		Manager
				Kim, James, Pharm.D., Dir. Clinical Account Services

		 Martinez, Chris, Sr. Business Analyst Killpack, Andy, Pharm.D., Dir. Specialty Clinical Solutions Managed Care Organization representatives present were as follows: Lim, Luke, Pharm.D., Anthem Bitton, Ryan, Pharm.D., Health Plan of Nevada Miro, Trashelle, Pharm.D., Silver Summit Health Plan Tran, Jimmy, Pharm.D., Molina Healthcare The public attendee list is included as Attachment A. Note: Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the attendee list's accuracy is not assured.
2. General Public Comment	Telephonic and web comment was called for, and the phone lines were opened. No public comment was provided.	
3. Administrative		
a. For Possible Action: Review and Approve Meeting Minutes from January 19, 2023.	Board Member Netochi moved to approve the minutes as presented, and Board Member England seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):	
	 Yes No Abst. Jennifer Wheeler, Pharm.D., Chair	

	• Netochi Adeolokun, Pharm.D., Vice Chair 🛛 🗌 🗌	
	,	
	Jessica Cate, Pharm.D.	
	Dave England, Pharm.D.	
	Brain Le, DO	
	Rebecca Sparks, PA-C	
	Jim Tran, Pharm.D. \square	
b. Status Update by DHCFP	 Chief of Pharmacy Services David Olsen provided five announcements. The 82nd Legislative Session is currently underway. Value legislature typically only meets on odd number of years. This session is currently scheduled to end on June 6th. Beginning July 1st of 2023 providers should begin contacting Magellan to obtain prior authorization for specific drugs for the Fee-for-Service recipients with date of service on or after July 1st. Providers will be able to complete the prior authorization process through either web or phone. Prior authorization will be required for medical specialty drugs when they are administered in the following places of service: physicians' offices, patient homes or outpatient facilities. Also, in addition to the prior authorization program, there will be a fee schedule for physician administered drugs starting in June. Please check the rates page on the DFCHP website for more information. If there any questions, please feel welcome to contact the Nevada Medicaid pharmacy services team at the RX Info e-mail listed on the agenda, it is <u>rxinfo@dhcfp.nv.gov</u>. We do have a notable staff change to report in the division. Doctor Antonina Capurro was serving as the Deputy Administrator over Medical Programs, which included the pharmacy services. She left the division at the end of last month. The pharmacy unit is now directly reporting to Stacie Weeks, 	

			who is the Administrator for the division. She is scheduled to	
			attend future DUR Board Meetings.	
4.	Clinica	al Presentations		
		or Possible Action:		
		scussion and possible		
		loption of prior		
		ithorization criteria and/or		
		antity limits for Verkazia		
	i.	Public comment on	Telephonic and web comment was called for, and the phone lines	
		proposed clinical prior	were opened.	
		authorization criteria.		
			No public comment was provided.	
	ii.	Presentation of	Dr. Raj Mishra provided the clinical background and indications for	
		utilization and clinical	Verkazia.	
		information.		
			Dr. Mishra reviewed the proposed criteria presented in the binder	
			and discussed the utilization of Verkazia.	
			• Dr. Lim with Anthem, approved of the proposed criteria and	
			utilization presented.	
			• Dr. Bitton with Health Plan of Nevada, approved of the proposed	
			criteria and utilization presented.	
			• Dr. Miro with Silver Summit Health Plan, approved of the	
			proposed criteria and utilization presented.	
			• Dr. Tran with Molina Healthcare, approved of the proposed	
			criteria and utilization presented.	
	iii.	Discussion by Board and	Chairperson Wheeler asked for comments from the Board Members.	
		review of utilization		
		data.	No comments were made.	
	iv.	Proposed adoption of	Board Member Tran moved to approve the criteria as presented by	
		updated prior	Magellan, and Board Member Canty seconded the motion.	
		authorization criteria.		
			A vote was taken, and the results were as follows from members in	
			attendance (in favor, against, and abstentions where applicable):	

	 Jennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice Chair Mark Canty, MD Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. 	Yes ⊠ ⊠ □ □ ∞ ∞ ∞	No	Abst.	
 b. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Epidiolex and Ztalmy. 					
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, were opened. Public comment was provided by Jennifer Shea Value and Outcomes with Jazz Pharmaceuticals	r Direc	·		
ii. Presentation of utilization and clinical information.	 Dr. Mishra provided the clinical background ar Epidiolex and Ztalmy. Dr. Mishra reviewed the proposed criteria presand discussed the utilization for Epidiolex and Dr. Lim with Anthem, approved of the proutilization presented. Dr. Bitton with Health Plan of Nevada, app criteria and utilization presented. 	d indi sented Ztalmy posed	in the /. criteria	binder a and	

review data.	sion by Board and v of utilization sed adoption of	 Dr. Miro with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. Chairperson Wheeler asked for comments from the Board Members. No comments were made. Board Member Canty moved to approve the criteria as presented by 			osed Members.	
•	ed prior rization criteria.	A vote was taken, and the results were as foll	Magellan, and Board Member Castaneda seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):			
		 Jennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice Chair Mark Canty, MD Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. 	Yes ⊠ ⊠ □ □ ∞ ∞ ∞	No	Abst.	
quantity lim i. <u>Public</u> propo	nd possible	Telephonic and web comment was called for were opened.	, and th	ne phor	ne lines	
		No public comment was provided.				

		Written public testimony from the Alzheimer's	Asson	iation	was sent	
ii.	Presentation of	Dr. Mishra provided the clinical background ar				
	utilization and clinical information.	Leqembi.		cations		
		Dr. Mishra reviewed the proposed criteria pre	sentec	l in the	binder	
		and discussed the utilization for Leqembi.				
		 Dr. Lim with Anthem, approved of the proutilization presented. Dr. Bitton with Health Plan of Nevada, approximation and utilization presented. Dr. Miro with Silver Summit Health Plan, a proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved criteria and utilization presented. 	proved	of the ed of th	proposed ne	
iii.	Discussion by Board and	Chairperson Wheeler asked for comments fro	m the	Board I	Members.	
	review of utilization data.	No comments were made.				
iv.	Proposed adoption of updated prior authorization criteria.	Board Member Castaneda moved to approve to presented by Magellan, and Board Member T motion.				
		A vote was taken, and the results were as follo attendance (in favor, against, and abstentions				
			Yes	No	Abst.	
		• Jennifer Wheeler, Pharm.D., Chair	\boxtimes			
		• Netochi Adeolokun, Pharm.D., Vice Chair	\boxtimes			
		Mark Canty, MD	\boxtimes			
		Crystal Castaneda, MD	\boxtimes			
		Jessica Cate, Pharm.D.			\boxtimes	
		Dave England, Pharm.D.	\boxtimes			

	Brain Le, DO	
	Rebecca Sparks, PA-C	
	• Jim Tran, Pharm.D.	
	, _	
d. For Possible Action:		
Discussion and possible		
adoption of prior		
authorization criteria and/or		
quantity limits for Abraxane .		
i. <u>Public comment</u> on	Telephonic and web comment was called for, and the phone lines	
proposed clinical prior	were opened.	
authorization criteria.		
	Public comment was provided by Dr. Janssen Sacro a Health Systems	
ii. Presentation of	Liaison, Medical Affairs Scientist for Bristol-Myers Squibb. Dr. Andy Killpack discussed the indications for Abraxane.	
utilization and clinical	DI. Andy Knipack discussed the indications for Abraxane.	
information.	Dr. Killpack reviewed the proposed criteria presented in the binder	
intornation.	and discussed the utilization of Abraxane.	
	• Dr. Lim with Anthem, approved of the proposed criteria and	
	utilization presented.	
	 Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. 	
	Dr. Miro with Silver Summit Health Plan, approved of the proposed criteria and utilization presented	
	proposed criteria and utilization presented.	
	• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.	
iii. Discussion by Board and review of utilization	Chairperson Wheeler asked for comments from the Board Members.	
data.	No comments were made.	
iv. Proposed adoption of	Board Member Castaneda moved to approve the criteria as	
updated prior	presented by Magellan, and Board Member Trans seconded the	
authorization criteria.	motion.	

		A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): Dr. Mark Canty had to leave the meeting.		
	 Jennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice Chair Mark Canty, MD Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. 	Yes ⊠ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □		Abst. □ □ □ □ □ □ □
e. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Bavencio.				
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, were opened. No public comment was provided.	and th	e phon	e lines
ii. Presentation of utilization and clinical information.	Dr. Killpack discussed the indications for Bave Dr. Killpack reviewed the proposed criteria pre and discussed the utilization of Bavencio.		d in the	e binder

review data. iv. Propos update	sion by Board and v of utilization sed adoption of ed prior rization criteria.	 Dr. Lim with Anthem, approved of the proutilization presented. Dr. Bitton with Health Plan of Nevada, approver and utilization presented. Dr. Miro with Silver Summit Health Plan, a proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approve criteria and utilization presented. Chairperson Wheeler asked for comments from No comments were made. Board Member Castaneda moved to approve presented by Magellan, and Vice Chair Adeolog motion. A vote was taken, and the results were as follow attendance (in favor, against, and abstentions) 	pproved d. d of the m the che crit okun se	of the ed of th e propo Board Board ceria as econde	proposed ne osed Members.	
		attendance (in favor, against, and abstentions	where Yes	e applio No	cable): Abst.	
		Jennifer Wheeler, Pharm.D., Chair Notochi Adoolokun, Bharm.D., Vice Chair	\boxtimes			
		Netochi Adeolokun, Pharm.D., Vice ChairMark Canty, MD	\square		\square	
		 Crystal Castaneda, MD 	\square			
		 Jessica Cate, Pharm.D. 			\square	
		 Dave England, Pharm.D. 	\boxtimes			
		Brain Le, DO			\boxtimes	
		Rebecca Sparks, PA-C	\boxtimes			
				_	_	
		• Jim Tran, Pharm.D.	\boxtimes			

	thorization criteria and/or antity limits for Beovu .					
i.	Public comment on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened.				
		No public comment was provided.				
ii.	Presentation of utilization and clinical information.		Dr. Killpack discussed the indications for Beovu. Dr. Killpack reviewed the proposed criteria presented in the binder			
		• Dr. Lim with Anthem, approved of the pro- utilization presented.	oosed	criteria	and	
		 Dr. Bitton with Health Plan of Nevada, app criteria and utilization presented. 				
		Dr. Miro with Silver Summit Health Plan, a		ed of th	ne	
		proposed criteria and utilization presented				
		Dr. Tran with Molina Healthcare, approved	of the	e propo	osed	
	Discussion by Decard and	criteria and utilization presented.		Deerd		
iii.	Discussion by Board and review of utilization	Chairperson Wheeler asked for comments fro	n the	Board	wembers.	
	data.	No comments were made.	•.			
iv.	Proposed adoption of updated prior authorization criteria.	Board Member England moved to approve the by Magellan, and Board Member Sparks secor		•		
		A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):				
			Yes	No	Abst.	
		• Jennifer Wheeler, Pharm.D., Chair	\boxtimes			
		• Netochi Adeolokun, Pharm.D., Vice Chair	\boxtimes			
		Mark Canty, MD			\boxtimes	
		Crystal Castaneda, MD	\boxtimes			
		Jessica Cate, Pharm.D.			\boxtimes	

	 Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. 	
g. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Bevacizumab.		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. No Public comment was provided.	
ii. Presentation of utilization and clinical information.	 Dr. Killpack discussed the indications for Bevacizumab. Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Bevacizumab. Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. Dr. Miro with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.	

iv. Proposed adoption of updated prior authorization criteria.	Board Member Sparks moved to approve the by Magellan, and Vice Chair Adeolokun secon A vote was taken, and the results were as follo attendance (in favor, against, and abstentions				
	 Jennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice Chair Mark Canty, MD Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. 	Yes ⊠ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □	No	Abst.	
 h. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Darzalex. 					
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, a were opened. No Public comment was provided.	and th	e phon	e lines	
ii. Presentation of utilization and clinical information.	No Public comment was provided. Dr. Killpack discussed the indications for Darzalex. Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Darzalex.				

iii. iv.	Discussion by Board and review of utilization data. Proposed adoption of updated prior authorization criteria.	 Dr. Lim with Anthem, approved of the proutilization presented. Dr. Bitton with Health Plan of Nevada, approximation and utilization presented. Dr. Beranek with Silver Summit Health Plan proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved criteria and utilization presented. Chairperson Wheeler asked for comments from No comments were made. Board Member Tran moved to approve the criteria model and Board Member Castaneda sector A vote was taken, and the results were as followed attendance (in favor, against, and abstentions) 	n, app d. d of th m the teria a unded	of the roved o e propo Board board the mo	proposed of the osed Members. ented by tion. nbers in	
		-				
i.	For Possible Action: Discussion and possible adoption of prior authorization criteria	- , -	_			

	and/or quantity limits for Darzalex Faspro .		
i.	Public comment on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened.	
		No Public comment was provided.	
ii.	Presentation of utilization and clinical	Dr. Killpack discussed the indications for Darzalex Faspro.	
	information.	Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Darzalex Faspro.	
		 Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. 	
		 Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. 	
		 Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. 	
		 Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	
iii.	Discussion by Board and review of utilization	Chairperson Wheeler asked for comments from the Board Members.	
	data.	No comments were made.	
iv.	Proposed adoption of updated prior authorization criteria.	Board Member Castaneda moved to approve the criteria as presented by Magellan, and Board Member Sparks seconded the motion.	
		A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):	
		Yes No Abst. ● Jennifer Wheeler, Pharm.D., Chair □ □ ● Netochi Adeolokun, Pharm.D., Vice Chair □ □	

		 Mark Canty, MD Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. 	
j.	For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Elaprase.		
i.	Public comment on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. No Public comment was provided.	
ii.	Presentation of utilization and clinical information.	 Dr. Killpack discussed the indications for Elaprase. Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Elaprase. Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	

iii. iv.	review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made. Board Member Castaneda moved to approve the criteria as presented by Magellan, and Vice Chair Adeolokun seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):					
		 Jennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice Chair Mark Canty, MD Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. 	Yes ⊠ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □	No	Abst.		
	For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Eylea.						
	Public comment on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. No Public comment was provided.					
	Presentation of utilization and clinical information.	Dr. Killpack discussed the indications for Eylea					

iii.	Discussion by Board and review of utilization data.	 Dr. Killpack reviewed the proposed criteria preand discussed the utilization of Eylea. Dr. Lim with Anthem, approved of the proutilization presented. Dr. Bitton with Health Plan of Nevada, apprication and utilization presented. Dr. Beranek with Silver Summit Health Plan proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved criteria and utilization presented. Dr. Tran with Molina Healthcare, for the proved criteria and utilization presented. Dr. Tran with Molina Healthcare, approved criteria and utilization presented. 	posed proved n, app d. d of th	criteria of the roved o e propo	a and proposed of the osed	
iv.	Proposed adoption of updated prior authorization criteria.	by Magellan, and Board Member Sparks second A vote was taken, and the results were as follo	Board Member England moved to approve the criteria as presented by Magellan, and Board Member Sparks seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):			
		 Jennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice Chair Mark Canty, MD Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. 	Yes ⊠ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □	No	Abst.	
I.	For Possible Action: Discussion and possible					

aut	option of prior thorization criteria and/or antity limits for Imfinzi .		
i.	Public comment on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. No Public comment was provided.	
ii.	Presentation of utilization and clinical information.	 Dr. Killpack discussed the indications for Imfinzi. Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Imfinzi. Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	
iii.	Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.	
iv.	Proposed adoption of updated prior authorization criteria.	Board Member Tran moved to approve the criteria as presented by Magellan, and Board Member Sparks seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):	
		 Yes No Abst. Jennifer Wheeler, Pharm.D., Chair Indexed Pharm.D., Vice Chair Indexed Pharm.D., Vice Chair Indexed Phark Canty, MD Mark Canty, MD Mark Canty Pharm.D., Vice Chair Indexed Pharm.D. Mark Canty, MD Mark Canty Pharm.D. Mark Phar	

		 Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. 			
m.	For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for intravenous Immune Globulin (IVIG).				
i.	Public comment on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. No Public comment was provided.			
ii.	Presentation of utilization and clinical information.	 Dr. Killpack discussed the indications for intravenous Immune Globulin (IVIG). Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of intravenous Immune Globulin (IVIG). Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 			

 iii. Discussion by Board and review of utilization data. iv. Proposed adoption of updated prior authorization criteria. 	Chairperson Wheeler asked for comments fro No comments were made. Board Member England moved to approve the by Magellan, and Vice Chair Adeolokun secon A vote was taken, and the results were as follo				
	attendance (in favor, against, and abstentions				
	 Jennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice Chair Mark Canty, MD Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. 	Yes ⊠ □ □ □ □ □ □ □ □ □ □ □ □ □		Abst.	
n. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Jemperli.					
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. No Public comment was provided.				
ii. Presentation of utilization and clinical information.	Dr. Killpack discussed the indications for Jemp Dr. Killpack reviewed the proposed criteria pre		d in the	e binder	

	and discussed the utilization of Jemperli.				
	• Dr. Lim with Anthem, approved of the pro utilization presented.	posed	criteria	a and	
	• Dr. Bitton with Health Plan of Nevada, app	roved	of the	proposed	
	criteria and utilization presented.				
	• Dr. Beranek with Silver Summit Health Pla	n, appi	roved o	of the	
	proposed criteria and utilization presented				
	• Dr. Tran with Molina Healthcare, approved	d of th	e propo	osed	
	criteria and utilization presented.				
iii. Discussion by Board and review of utilization	Chairperson Wheeler asked for comments fro	m the	Board	Members.	
data.	No comments were made.				
iv. Proposed adoption of	Board Member Tran moved to approve the cri		•	•	
updated prior authorization criteria.	Magellan, and Board Member Sparks seconde	a the	motion	•	
	A vote was taken, and the results were as follo	ws fro	m mer	nhers in	
	attendance (in favor, against, and abstentions				
				,	
		Yes	No	Abst.	
	Jennifer Wheeler, Pharm.D., Chair	\boxtimes			
	Netochi Adeolokun, Pharm.D., Vice Chair	\boxtimes			
	Mark Canty, MD			\boxtimes	
	Crystal Castaneda, MD	\boxtimes			
	• Jessica Cate, Pharm.D.			\boxtimes	
	• Dave England, Pharm.D.	\boxtimes			
	Brain Le, DO			\boxtimes	
	Rebecca Sparks, PA-C	\boxtimes			
	• Jim Tran, Pharm.D.	\boxtimes			
o. For Possible Action:					
Discussion and possible					
adoption of prior					

	thorization criteria and/or antity limits for Kadcyla .					
i.	Public comment on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, a were opened.	and the	e phon	e lines	
ii.	Presentation of utilization and clinical information.	Dr. Killpack discussed the indications for Kadcy	No Public comment was provided. Dr. Killpack discussed the indications for Kadcyla. Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Kadcyla.			
		 Dr. Lim with Anthem, approved of the projutilization presented. Dr. Bitton with Health Plan of Nevada, appcriteria and utilization presented. Dr. Beranek with Silver Summit Health Plan proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved criteria and utilization presented. 	roved n, appr l.	of the roved c	proposed of the	
iii.	Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments fro	m the	Board	Members.	
iv.	Proposed adoption of updated prior authorization criteria.	No comments were made. Vice Chair Adeolokun moved to approve the criteria as presented by Magellan, and Board Member Castaneda seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):				
		 Jennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice Chair Mark Canty, MD Crystal Castaneda, MD 	Yes	No	Abst.	

p. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or	 Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. 	
quantity limits for Keytruda .		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. No Public comment was provided.	
ii. Presentation of utilization and clinical information.	 Dr. Killpack discussed the indications for Keytruda. Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Keytruda. Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.	

iv. Proposed adoption of updated prior authorization criteria.	Board Member England moved to approve the by Magellan, and Vice Chair Adeolokun second A vote was taken, and the results were as follo attendance (in favor, against, and abstentions				
	 Jennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice Chair Mark Canty, MD Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. 	Yes ⊠ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □	No	Abst.	
 q. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Libtayo. 					
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, a were opened. No Public comment was provided.				
ii. Presentation of utilization and clinical information.	Dr. Killpack discussed the indications for Libtay Dr. Killpack reviewed the proposed criteria pre and discussed the utilization of Libtayo.		d in the	e binder	

		 Dr. Lim with Anthem, approved of the proutilization presented. Dr. Bitton with Health Plan of Nevada, approximation and utilization presented. Dr. Beranek with Silver Summit Health Plan proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved criteria and utilization presented. 						
iii.	Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.						
iv.	Proposed adoption of updated prior authorization criteria.	Board Member Castaneda moved to approve to presented by Magellan, and Board Member T motion. A vote was taken, and the results were as follo attendance (in favor, against, and abstentions						
		 Jennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice Chair Mark Canty, MD Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. 	Yes ⊠ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □	No	Abst.			
	oard Requested Reports oid Reports: Opioid Trends	 Dr. Mishra presented opioid utilization rep Dr. Lim presented opioid utilization reports 	orts.					

 ii. Count of Claims iii. Med Trend iv. Top Members v. Top Prescribers vi. Top Pharmacy 	 Dr. Bitton presented opioid utilization reports. Dr. Miro presented opioid utilization reports. Dr. Tran presented opioid utilization reports. Chairperson Wheeler asked for comments from Board Members regarding Opioid Reports. The board discussed utilization and trends. No additional action taken or motions for investigative referrals.
 b. Standard DUR Reports: Top 10 Classes by Amount Paid Top 10 Classes by Claim Top 10 Classes by Claim Count Quarterly ProDUR Paid Claims Saving Report Retro DUR Initiatives 	 Dr. Mishra presented Standard DUR Reports Dr. Lim presented Standard DUR Reports. Dr. Bitton presented Standard DUR Reports Dr. Miro presented Standard DUR Reports Dr. Tran presented Standard DUR Reports.
6. Closing Discussion	
a. Public Comment	Telephonic and web comment was called for, and the phone lines were opened. No public comment was provided.
b. For Possible Action: Date and location of the next meeting.	Chairperson Wheeler stated the next meeting is scheduled for July 20, 2023. Location: Hilton Garden Inn Reno
	Meeting adjourned at 3:21 pm

Attachment A – Members of the Public in Attendance

Michael	Pazirandeh	Tammy	Buist	Mark	Rosenberg	Deb	Guay
Tina	Hartmann	Susan	Hertzberg	Jake	Matthews	Elyse	Monroy
Todd	Dickerson	Gina	Heinen	Joseph	Germain Jr.	Ronald	Matteotti
Fabiola	Garcia	Sara	Gao	Chris	Johnson	Maria	Reyes
Kevin	Chang	Gary	Parenteau	Jeana	Colabianchi	Amy	Hale
Lisa	Pulver	Bobby	White	Christy	Nguyen	Karen	Ou
Heather	Williamson	Jennifer	Shear	KayOnda	Вауо		
Janssen	Sacro	Joe	Germain	Geoffrey	Robinson		
Sung	Park	Chris	Santarone	Angela	Daughtridge		
Camille	Kerr	Jennifer	Davis	Mark	Paskett		

Attachment B – Submitted Written Comment

Alzheimer's Association